Calcium Disodium Versenate — Competitive Intelligence Brief

Calcium Disodium Versenate (EDETIC ACID) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-coagulant. Area: Rare Disease.

marketed Anti-coagulant Amyloid beta A4 protein Rare Disease Small molecule

Target snapshot

Calcium Disodium Versenate (EDETIC ACID) — Medicis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Calcium Disodium Versenate TARGET	EDETIC ACID	Medicis	marketed	Anti-coagulant	Amyloid beta A4 protein	1953-01-01
Leqembi	LECANEMAB	Eisai	marketed	Amyloid Beta-directed Antibody [EPC]	Amyloid beta A4 protein	2023-01-01
Aduhelm	ADUCANUMAB	Biogen	marketed	Amyloid Beta-directed Antibody	Amyloid beta A4 protein	2021-01-01
Neuraceq	FLORBETABEN F18	Piramal Imaging	marketed	Radioactive Diagnostic Agent [EPC]	Amyloid beta A4 protein	2014-01-01
Vizamyl	Flutemetamol (18F)	GE HealthCare	marketed	Radioactive Diagnostic Agent [EPC]	Amyloid beta A4 protein	2013-01-01
Amyvid	FLORBETAPIR F 18	Avid Radiopharms Inc	marketed	Radioactive Diagnostic Agent [EPC]	Amyloid beta A4 protein	2012-01-01
M.V.I. Pediatric	RETINOL	Pfizer	marketed	Vitamin A	Amyloid beta A4 protein	1953-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2027-04-30 — Amyvid · 8506929 · US
• 2027-04-30 — Amyvid · 7687052 · US
• 2028-09-16 — Vizamyl · 8916131 · US
• 2029-03-18 — Neuraceq · 7807135 · US

Sponsor landscape (Anti-coagulant class)

1. · 1 drug in this class
2. Baxter · 1 drug in this class
3. Fresenius Kabi · 1 drug in this class
4. Marathon Pharms Llc · 1 drug in this class
5. Medicis · 1 drug in this class
6. Merck & Co. · 1 drug in this class